Systemic inflammatory response syndrome associated with amifostine.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Medical and Pediatric Oncology

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1096-911X(200004)34:4<309::AID-MPO25>3.0.CO;2-XPMID 10742082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fever and rash after amifostine therapy.

  1998cited by this paper
• Pharmacokinetics of amifostine and its metabolites in patients.

  1997cited by this paper
• Hypotensive Mechanisms of Amifostine

  1996cited by this paper
• Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma

  1992cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy.

  1988cited by this paper

• Pulmonoprotective Action of Zataria multiflora Ethanolic Extract on Cyclophosphamide-Induced Oxidative Lung Toxicity in Mice

  2018cites this paper
• Síndrome da resposta inflamatória sistêmica: denominação possivelmente aplicável a fenômenos dermatológicos

  2007cites this paper
• Effect of squalene on cyclophosphamide-induced toxicity.

  2006cites this paper
• Modulation of the tissue defense system by squalene in cyclophosphamide induced toxicity in rats

  2006cites this paper
• Attenuation of cyclophosphamide induced toxicity by squalene in experimental rats.

  2006cites this paper
• Amifostine‐Induced Fever: Case Report and Review of the Literature

  2004cites this paper
• In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. implications in cancer chemotherapy.

  2003cites this paper
• Amifostine in clinical oncology: current use and future applications

  2002cites this paper
• Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection

  2002cites this paper